Abstract Library

#2940 Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated, Grade 3 Neuroendocrine Carcinomas (NECs)

Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rodriguez-Freixinos V

Authors: Rodriguez-Freixinos V, Chan D, Doherty M, Wasson K, Iscoe N,

Keywords: Poorly differentiated, G3 NECs, Avelumab, Immunotherapy,

#2821 Nucleophosmin Expression and Relocation in Pancreatic Neuroendocrine Tumors: Preliminary Data

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms with unpredictable clinical course and biological behavior. Nucleophosmin (NPM) is an important multifunctional protein mainly located in the nucleolus. NPM has been reported to be overexpressed in many types of human cancer, activating tumor development and progression. However, the role of NPM in PanNETs is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Delektorskaya V, Bukaeva I, Ponomareva M, Smirnova E,

Keywords: neuroendocrine tumor, pancreas, nucleophosmin, immunohistochemistry, prognosis,

#2071 ElevatION:NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti–PD-1 and anti–PD-L1, have become established treatment options in various solid tumors. However, there is a paucity of data on treatment effect of checkpoint inhibition in neuroendocrine tumors (NET) and neuroendocrine carcinoma (NEC). PDR001 is a high-affinity, humanized IgG4 mAb directed against PD-1 that blocks the binding of PD-L1 and PD-L2 to PD-1.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Yao J, Fazio N, Li D, Pavel M, Strosberg J,

Keywords: PDR001, immunotherapy, NET,

#1797 An Open-Label Phase II Study to Evaluate the Efficacy and Safety Of PDR001 in Patients with Advanced Well-Differentiated Non-Functional NET of Pancreatic, Gastrointestinal (GI), or Thoracic Origin Who Have Progressed on Prior Treatment

Introduction: Monoclonal antibody (mAb) inhibitors of immune checkpoints, including anti-PD-1 and anti-PD-L1, have become established treatment (tx) options in various solid tumors. However, there is a paucity of data on checkpoint inhibitors in NET. In a phase I trial of PDR001 (mAb checkpoint inhibitor targeting PD-1) conducted in patients (pts) with multiple solid tumor types, a pt with histologically confirmed metastatic atypical pulmonary carcinoid demonstrated a RECIST-based tumor response and clinical benefit.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Yao J

Authors: Yao J, Fazio N, Pavel M, Strosberg J, Bergsland E,

Keywords: PDR001, immunotherapy, NET,

#1653 Expression and Clinical Significance of Somatostatin Receptor Subtype 2A in Small Cell Lung Carcinoma

Introduction: Somatostatin receptors (SSTRs) play a key role in the regulation of cell proliferation and have been identified in a proportion of aggressive poorly differentiated neuroendocrine neoplasms, including small cell lung carcinomas (SCLCs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Delektorskaya V, Kusminov A, Ivanov A, Gorbunova V,

Keywords: small cell carcinoma, lung, immunohistochemistry,